A Study Testing the Safety and Effects of FB102 in Healthy Volunteers
← catalyst calendarNCT07623057 · readout ≤ 193 d
Sponsored by Forte Biosciences, Inc. (industry) · FBRX — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
48estimated
Sites
2
Country
Australia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-23 | actual | When the study began enrolling |
| Primary completion | Feb 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteer
Interventions
- Drug: FB102 Single dose — also filed as Healthy Volunteer
- Drug: FB102 Multiple doses — also filed as Healthy Volunteer
- Drug: FB102 Placebo — also filed as Healthy Volunteer
Primary outcomes
what the primary-completion date above is the date OFIncidence, severity, and relationship to treatment of treatment-emergent adverse events (TEAEs)
measured From day 1 to Day 85 (End of treatment visit)
Incidence, severity, and relationship to treatment of SAEs
measured From day 1 to Day 85 (End of treatment visit)
Permalink · FBRX's whole pipeline · Catalyst calendar · Every registered study · What changed